1. Gupta SK, Prakash J, Awor L, Joshi S, Velpandian T, Sengupta S. Anti-inflammatory activity of topical nimesulide gel in various experimental models. Inflamm. Res. 1996; 45: 590-592
2. Gupta SK, Velpandian T, Mathur P, Sengupta S. Comparative analgesic activity of nimesulide and diclofenac by intramuscular route: correlation with pharmacokinetic profile of nimesulide. Pharmacology 1998; 56: 137-143
3. Gupta SK, Velpandian T, Sengupta S, Mathur P, Sapra P. Influence of piperine on nimesulide induced antinociception. Phytother. Res. 1998;12: 266-269
4. Sengupta S, Velpandian T, Sapra P, Mathur P, Gupta S K. Comparative analgesic efficacy of nimesulide and diclofenac gels after topical application on the skin. Skin Pharmacol. Appl. Skin Physiol.1998;11: 273-278
5. Velpandian T, Mathur P, Sengupta S, Gupta S K. Preventive effect of chyavanprash against steroid induced cataract in the developing chick embryo. Phytother. Res. 1998; 12: 320-323
6. Sengupta S, Velpandian T, Kabir SR, Gupta S K. Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo. Eur J Clin Pharmacol 1998; 54: 541-547
7. Sengupta S, Tyagi P, Velpandian T, Gupta Y K, Kochupillai V, Gupta S K. Evaluation of the antitumour activity of liposomal formulations of etoposide against choriocarcinoma xenografts in balb/c nu/nu mice. Pharm. Pharmacol. Commun. 1999; 5: 595-598
8. Sengupta S, Sanyal M, Kochupillai V, Gupta S K. Expression of inducible and neuronal nitric oxide synthase in 20-methyl cholanthrene (20-mca) induced fibrosarcoma. Ind. J. Pharmacology 1999; 31: 315-318
9. Gupta SK, Bhardwaj RK, Tyagi P, Sengupta S, Velpandian T. Anti-inflammatory activity and pharmacokinetic profile of a new parenteral formulation of nimesulide. Pharmacological Research 1999; 39: 137-141
10. Sengupta S, Tyagi P, Velpandian T, Gupta Y K, Gupta S K. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacological Research. 2000; 42: 459-464
11. Sengupta S, Tyagi P, Chandra S, Kochupillai V, Gupta S K. Encapsulation in cationic liposomes enhances antitumour efficacy and reduces the toxicity of etoposide, a topo-isomerase ii inhibitor. Pharmacology. 2001; 62: 163-71
12. Sengupta S, Sellers LA, Cindrova T, Skepper JN, Gherardi E, Sasisekheran R, Fan TP. Cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis. Cancer Res. 2003; 63: 8351-8359
13. Sengupta S, Seller LA, Li R, Zhao G, Gherardi E, Sasisekharan R, Fan TP. Targeting of mitogen activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation 2003; 107: 2955-2961
14. Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vitro and in vivo: an evaluation of possible mechanisms. Br. J. Pharmacol. 2003; 139: 219-231
15. Sengupta S, Gherardi E, Sellers LA, Sasisekharan R, Fan TP. Hepatocyte growth factor/scatter factor can induce angiogenesis independent of vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 69-7
16. Qi Y, Zhao G, Liu D, Shriver Z, Sundaram M, Sengupta S, Venkataraman G, Langer R, Sasisekharan R. Delivery of therapeutic levels of heparin and low molecular weight heparin through a pulmonary route. Proc. Natl. Acad. Sci. (USA) 2004; 101: 9867-9872
17. Sengupta S, Kiziltepe T, Sasisekharan R. A dual color fluorescence imaging-based system for the dissection of the antiangiogenic and chemotherapeutic properties of molecules. FASEB J. 2004; doi:10.1096/fj.04-1934fje
18. Johnson NA, Sengupta S, Saidi SA, Lessan K, Charnock-Jones SD, Scott L, Stephens R, Freeman TC, Tom BDM, Harris M, Denyer G, Sundaram M, Sasisekharan R, Smith SK, Print CG. Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation. FASEB J. 2004; 18: 188-190
19. Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, Yeung HW, Wong RNS, Sasisekharan R, Fan TP. Modulating angiogenesis- the yin and the yang in ginseng. Circulation 2004; 104: 1219-1225
20. Sengupta S, Sellers LA, Gherardi E, Sasisekharan R, Fan TP. Nitric oxide modulates hepatocyte growth factor induced angiogenesis. Angiogenesis 2004; 7: 285-94
21. Sengupta S, Eavarone DA, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Novel cancer therapy through temporal targeting of both tumor cells and neovasculature using a unique nanoscale delivery system. Nature 2005; 436: 568-72
This was the first study to describe a layer-by-layer nanoparticles for targeting different compartments of a tumor.
22. Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br. J. Cancer. 2007; 96:1315-9
23. Sorathyia A, Jucikas T, Piecewicz S, Sengupta S, Lio P. Searching for glycomics role in vasculogenesis. Lecture Notes in Bioinformatics. 2008; 198-209
24. Agarwal S, Sengupta S. Ranking genes by relevance to a disease. Proc. LSS. Comput. Syst. Bioinform Conf. 2009; 37-46
25. Harfouche R, Basu S, Soni S, Hentschel D, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009; 12: 325-38
26. Chaudhuri P, Paraskar A, Soni S, Mashelkar RA, Sengupta S. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano. 2009; 3: 2505-14
27. Harfouche R, Hentschel D, Piecewicz, Basu S, Print C, Eavarone D, Kiziltepe T, Sasisekharan R, Sengupta S. Glycome and transcriptomal regulation of vasculogenesis. Circulation 2009; 120: 1883-92
This was the first study to demonstrate that the sulfation of GAGs is critical during differentiation of embryonic stem cells into vasculature.
28. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of mapk signaling predisposes tumor to chemotherapy. Proc. Natl. Acad. Sci. (U S A) 2009; 106: 7957-61
This was the first study to use nanoparticles for targeting signal transduction pathways.
29. Basu S, Chaudhuri P, Sengupta S. Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle. 2009; 8: 3480-7
30. Chaudhuri P, Soni S, Sengupta S. Single-walled carbon nanotube-conjugated chemotherapy exhibit increased therapeutic index in melanoma. Nanotechnology. 2010; 21: 025102
31. Chaudhuri P, Harfouche R, Soni S, Hentschel DM, Sengupta S. Shape effect of carbon nanovectors on angiogenesis. ACS Nano. 2010; 4: 574-82
32. Agarwal S, Dugar D, Sengupta S. ranking chemical structures for drug discovery: a new machine learning approach. J. Chem. Inf. Model. 2010; 50: 716-31
33. Sinha Roy R, Soni S, Harfouche R, Vasudevan P, Holmes O, de Jonge H, Rowe A, Paraskar A, Hentschel DM, Gherardi E, Mashelkar RA, Sengupta S. Coupling growth factor engineering with nanotechnology for therapeutic angiogenesis. Proc. Natl. Acad. Sci. (USA) 2010; 107: 13608-13
This was the first study to use nanoparticles for targeting signal transduction pathways.
34. Paraskar A, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S. Harnessing structure-activity relationship to engineer a novel cisplatin nanoparticle for improved antitumor efficacy. Proc. Natl. Acad. Sci. (USA) 2010; 107: 12435-40
35. Banerjee D, Harfouche R, Sengupta S. Targeting angiogenesis using nanotechnology. Vasc. Cell 2011; 3: 3
36. Kohandel M, Haselwandter C, Kardar M, Sengupta S, Sivaloganathan S. Quantitative model for efficient temporal targeting of tumor cells and neovasculature. Comput. Math. Methods. Med. 2011; 790721
37. Sengupta P, Basu S, Sengupta S. Targeting signal transduction pathways in cancer using nanotechnology. Current Drug Deliv. 2011; 8: 254-60
38. Piecewicz S, Sengupta S. The dynamic glycome microenvironment and stem cell differentiation into vasculature. Stem Cell and Development 2011; 20: 749-58
39. Roy RS, Roy B, Sengupta S. Emerging technologies for enabling proangiogenic therapy. Nanotechnology. 2011; 22: 494004
40. Banerjee D, Sengupta S. Nanoparticles in cancer chemotherapy. Prog. Mol. Biol. Transl. Sci. 2011; 104: 489-507
41. Paraskar A, Soni S, Basu S, Amarasiriwardena CJ, Lupoli N, Srivats S, Roy RS, Sengupta S. Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology. 2011; 22: 265101
42. Piecewicz SM, Pandey A, Roy B, Hua Xiang S, Zetter BR, Sengupta S. Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One. 2012; 7: e32191
43. Sengupta P, Basu S, Soni S, Pandey A, Oh M, Chin KT, Paraskar AS, Roy B, Sarangi S, Connor Y, Sabbisetti V, Kopparam J, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, Bonventre JV, Mashelkar RA, Sengupta S. A cholesterol-tethered platinum ii-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc. Natl. Acad. Sci. (USA), 2012; 109: 11294-9
Here we described the use of SAR in designing an effective Pt-based nanoparticle.
44. Papa AL, Basu S, Sengupta P, Banerjee D, Sengupta S, Harfouche R. mechanistic studies of gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer. 2012; 12: 419
45. Paraskar A, Soni S, Roy B, Papa AL, Sengupta S. Rationally designed oxaliplatin nanoparticle for enhanced antitumor efficacy. Nanotechnology. 2012; 23: 075103
46. Sarangi S, Pandey A, Papa AL, Sengupta P, Kopparam J, Dadwal U, Basu S, Sengupta S. P2Y12 Receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Med. Oncol. 2013; 30: 567
47. Kulkarni AK, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu B, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S. Supramolecular nanoparticles that target phosphatidylinositol-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res. 2013; 73: 6987-97
48. Papa A, Sidiqui A, Balasubramanian SUA, Sarangi S, Luchette M, Sengupta S, Harfouche R. Pegylated liposomal gemcitabine: insights into a potential breast cancer therapeutic. Cell Oncol. 2013; 36: 449-57
49. Sengupta S, Kulkarni A. Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano. 2013; 7: 2878-82
50. Sengupta S. Clinical translational challenges in nanomedicine. MRS Bull. 2014. 39: 259-264
51. Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, Phipps C, Kopparam J, Oh M, Basu S, Kohandel M, Sengupta S. Mathematically modeling the sequential application of a cytotoxic nanoparticle and a pi3k-inhibitor enhances anti-tumor efficacy. Cancer Res. 2014; 74: 675-85
52. Pandey A, Sarangi S, Chien K, Sengupta P, Papa AL, Basu S, Sengupta S. anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery. Nanotechnology. 2014; 25: 445101
53. Connor Y, Tekleab S, Nandakumar S, Walls C, Tekleab Y, Husain A, Gadish O, Sabbisetti V, Kaushik S, Sehrawat S, Kulkarni A, Dvorak H, Zetter B, Edelman E, Sengupta S. Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. Nature Commun. 2015; 6: 8671
54. Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu G, Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim R, Agarwal S, Sengupta S*, Sundaram M*, Majumder PK*. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nature Commun. 2015; 6: 6169 (*equal senior contribution)
55. Goldman A. Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, Majumder MK, Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nature Commun. 2015; 6: 6139
56. Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, Dover JS, Sengupta S. Antibiotic-resistant acne: getting under the skin. Semin Cutan Med Surg. 2016; 35: 62-7
57. Boareto M, Jolly MK, Goldman A, Pietilä M, Mani SA, Sengupta S, Ben-Jacob E, Levine H, Onuchic JN. Notch-jagged signalling can give rise to clusters of cells exhibiting a hybrid epithelial/mesenchymal phenotype. J R Soc Interface. 2016; 13pii: 20151106
58. Molavian HR, Goldman A, Phipps CJ, Kohandel M, Wouters BG, Sengupta S, Sivaloganathan S. Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. Sci Rep. 2016; 6: 27439
59. Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, Ghosh S, Sardana K. Heterogeneity and antibiotic resistance in Propionibacterium acnes strains and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. Dermatol Ther. 2016. doi: 10.1111/dth.12391
60. Kulkarni AA, Rao P, Natarajan S, Goldman A, Sabbisetti V, Khater Y, Korimerla N, Mashelkar R, Sengupta S. “Reporter nanoparticle that monitors its anticancer efficacy in real time.”, Proc Natl Acad Sci U S A, 2016; 1: E2104-13
Editor’s Choice article on the above publication:
Kostic M. Seeing is believing. Cell Chemical Biology. 2016; 23: 428
Editorial survey on the above article:
Atala A. Urological Survey on Re: Reporter Nanoparticle that Monitors its Anticancer Efficacy in Real Time. The Journal of Urology. 2016; 196; 1313-1314
61. Kulkarni AA, Natarajan SK, Chandrasekar V, Pandey P, Sengupta S. “Combining immune checkpoint inhibitors and kinase-inhibiting supramolecular therapeutics for enhanced anti-cancer efficacy”, ACS Nano. 2016; 10: 9227–9242
62. Kulkarni AA, Pandey P, Rao P. S., Wyant G., Mahmoud A, Goldman A, Kotamraju VR, Ruoslahti E, Dinulescu D, Roy S, Sengupta S. “Algorithm for designing nanoscale supramolecular therapeutics with increased anticancer efficacy”, ACS Nano. 2016; 10: 8154-68.
Perspective article on the above publication:
Decuzzi P. Facilitating the Clinical Integration of Nanomedicines: The Roles of Theoretical and Computational Scientists, ACS Nano. 2016 10 (9), 8133-8138
63. Goldman A, Kulkarni AA, Kohandel M, Pandey PR, Natarajan S, Ravi S, Sabbisetti S, Sengupta S. “Rationally designed 2-in-1 nanoparticles can overcome adaptive resistance in cancer”, ACS Nano. 2016; 10: 5823-5824
64. Kulkarni AA, Vijaykumar VE, Natarajan SK, Sengupta S, Sabbisetti VS. “Sustained inhibition of cmet-vegfr2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer”, Nanomedicine: Nanotechnology, Biology and Medicine. 2016; 12: 1853-1861
65. Calibasi Kocal G, Güven S, Foygel K, Goldman A, Chen P, Sengupta S, Paulmurugan R, Baskin Y, Demirci U. Dynamic microenvironment induces phenotypic plasticity of esophageal cancer cells under flow. Sci Rep. 2016; 6: 38221
66. Gupta N, Kancharla J, Kaushik S, Ansari A, Hossain S, Goyal R, Pandey M, Sivaccumar J, Hussain S, Sarkar A, Sengupta A, Mandal SK, Roy M, Sengupta S. Development of a facile antibody-drug conjugate platform for increased stability and homogeneity. Chemical Sciences. 2017; 8: 2387-2395
67. Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S. Evaluation of therapeutic potential of vb-001, a leave-on formulation, for the treatment of moderate adherent dandruff. BMC Dermatol. 2017; 17: 5
68. Sengupta S. Cancer nanomedicine: lessons for immuno-oncology. Trends in Cancer. 2017 (In press)
69. Kulkarni A, et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nature Biomedical Engineering. 2018; 2: 589-599
News and Views by
Heather H. Gustafson & Suzie H. Pun Instructing macrophages to fight cancer. Nature Biomedical Engineeringvolume 2, pages559–561 (2018
70. Ghosh S, et al. A Rationally Designed Multifunctional Antibiotic for the Treatment of Drug-Resistant Acne. J Invest Dermatol. 2018;138(6):1400-1408
Book chapters, monographs
71. Sengupta S, Fan T-P D. Immunity. In The Oxford Companion to the Body. Blakemore C and Jennett S, editors. Oxford, UK: Oxford University Press, 2001. pp 86
72. Sengupta S, Fan T-P D. Autoimmune diseases. In The Oxford Companion to the Body. Blakemore C and Jennett S, editors. Oxford UK: Oxford University Press, 2001. pp 54-55
73. Sengupta S, Gupta S K. Angiogenesis: Concepts and research methodologies. In Pharmacology and Therapeutics in the New Millennium. Gupta SK, editor. New Delhi, India: Springer, 2001. pp.191-204
74. Sengupta S. Angiogenesis. In Drug Screening Methods. Gupta SK, editor. New Delhi, India: Jaypee Brothers Medical Publishers, 2009. pp 99-115.
75. Mashelkar RA, Patwardhan B, Sengupta S. Emerging innovation practices and policies for the healthcare needs of resource-poor people. Global Forum Update on Research for Health. 2009. 6: pp 153-156.
76. Chaudhuri P, Harfouche R, Sengupta S. The Bittersweet Promise of Glycobiology. In Biomarkers: In Medicine, Drug Discovery, and Environmental Health. Vaidya VS and Bonventre JV, editors. Hoboken N.J.: Wiley Press, 2010. pp 75-88.
77. Banerjee D, Sengupta S. Nanoparticles in Cancer Chemotherapy. In Nanoparticles in translational science and medicine. Villaverde A, editor. Vol. 104 in the series: Progress in molecular biology and translational science: Waltham, MA: Academic Press. 2011. pp 489-504
Selected conference papers
78. Piecewicz S, Sengupta S, Hentschel DM. Chemical genetic analysis of glycome regulation in vasculogenesis. Experimental Biology Conference, 2007. Washington D.C.
This paper was selected as one of the four finalists for the ASPET best paper award
79. Piecewizc S, Harfouche R, Hentschel D, Basu S, Sengupta S. A novel embryonic stem cell differentiation system for high-throughput antiangiogenesis screening. Experimental Biology, 2009. New-Orleans, Louisiana. Published in FASEB J. 2009: 23: 756.11
This submission was selected for the best paper award by ASPET
80. Sinha-Roy R, Soni S, Harfouche R, Vasudevan PR, Paraskar A, Sengupta S. Integrating novel protein engineering and nanotechnology for therapeutic angiogenesis. Experimental Biology Meeting, 2010. Published in FASEBJ. 2010; 24: 518
This submission was selected as a finalist for the best paper award
81. Connor Y, Harfouche R, Liu C, Oh M, Sengupta S. Modeling interactions between endothelial cells and metastatic breast cancer cells in a three-dimensional culture. AACR 101st Annual Meeting, Washington, DC 2010; Abstract 4813
This submission was selected for a spotlight presentation
82. Connor YD, Tekleab S, Gill NK, Bharat D, Lloyd T, Walls CR, Sengupta S. Intercellular transfer between metastatic breast cancer and the endothelium mediated by tunneling nanotubes. AACR Annual Meeting, Chicago, IL, 2012. Published in Cancer Res. 2012; 72: 4222
Connor YD Awarded the AACR Minority Scholar in Training Award for this paper
83. Kulkarni AA, Rao P, Goldman A, Sengupta S. Computationally-inspired engineering of supra-molecular taxane nanoparticles. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Published in Cancer Res. 2014; 74 (19 Suppl): Abstract: 5419.
Kulkarni AA was awarded an AACR Bristol-Myers-Squibb Scholar-in-Training prize from AACR for this paper
84. Roy M, Hossain SKS, Sarkar A, Sengupta A, Gupta A, Hussain S, Ansari A, Mylavarapu S, Sengupta S. IO125, a novel pt-based supramolecular therapeutic exhibits increased anti-cancer efficacy compared with oxaliplatin. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, 2014; San Diego, CA. Published in Cancer Res. 2014; 74 (19 Suppl): Abstract: 4483
85. Kulkarni A, Rao P, Goldman A, Sengupta S. Targeting chemotherapy induced adaptive resistance using hybrid nanoparticles (LB577). Experimental Biology Meeting, San Diego, CA, April 2014. Published in The FASEB Journal, 2014; 28: LB577
Ashish Kulkarni was awarded a Young Scientist Travel Award for this paper
86. Sadhasivam S, Saini S, Kaur SP, Gupta T, Sardana K, Buchta R, Sengupta S, Ghosh S. Analysis of antibiotic resistance of propionibacterium acnes and other bacterial populations in the skin microbiomes of acne vulgaris patients in india. ICAAC/ICC, 2015, San Diego, California
87. Gupta N, Kancharla J, Kaushik S, Hossain S, Sarkar A, Sengupta A, Roy M, Sengupta S. Supramolecular assembly of antibody-drug conjugates using cordlink platform for targeted drug delivery. AACR 2015, Abstract Number: 649
88. Sengupta A, Mylavarapu S, Kumari S, Hossain S, Heeralal B, Gupta N, Sarkar A, Ansari A, Velpandian T, Roy M, Sengupta S. A novel supramolecular platinum chemotherapy being developed in triple-negative breast cancer. ASCO Breast Cancer Symposium, Abstract number 155134. 2015, San Diego, CA, USA
89. Roy M, Sengupta A, Sarkar A, Mylavarapu S, Modi S, Gupta N, Heeralal B, Hossain S, Ansari A, Pandey M, Yadav Y, Sengupta S. Designing a novel platinum chemotherapeutic (io-125) for treatment of breast cancer. San Antonio Breast Cancer Symposium, 2015, Program Number: P5-03-03, San Antonio, TX, USA
90. Bhattacharyya A, Sinha M, Sadhasivam S, Patel RS, Mandal D, Ghosh S, Sengupta S. A mechanistic and translational study of the antimicrobial effects of molecular replacement in malassezia. ICAAC/ICC, 2015, San Diego, CA, USA
91. Ghosh S, Sinha M, Sadhasivam S, Usharani D, Reddy S, Bhattacharyya A, Mishra M, Saini S, Kumar D, Patel RS, Ghosh S, Buchta R, Sengupta S. A novel antibiotic with reduced propensity to develop resistance. ICAAC/ICC, 2015, San Diego, CA, USA
92. Sadhasivam S, Ghosh S, Sinha M, Reddy S, Bhattacharyya A, Mishra M, Saini S, Kumar D, Patel RS, Ghosh S, Buchta R, Sengupta S. Antibiotic resistance crisis: a novel approach towards developing an effective regime. 5th Annual Conference of the Clinical Infectious Diseases Society, (CIDSCON) 2015, New Delhi, India
93. Kulkarni A, Pandey P, Rao P, Goldman G, Roy S, Sengupta S. Engineering of supramolecular taxane nanoparticles by computationally modeling drug-lipid bilayer interactions. Experimental Biology Meeting, 2015, Boston, MA. The FASEB Journal vol. 29 no. 1 Supplement 620.7
Kulkarni A awarded Young Scientist Travel Award for this paper
94. Chandrasekar V, Natarajan SK, Sengupta S, Kulkarni A. A. “Supramolecular fusion nanotherapeutic- mediated synergistic inhibition of pi3k and mek pathways”, AACR Annual Meeting, 2016, New Orleans, LA
This paper was selected for the best poster prize to Chandrasekar V
95. Natarajan S, Sengupta S, Kulkarni AA. “2-in-1 ‘Sniper’ nanomedicines rescue dendritic cells by two pronged inhibition of jak2/stat-3 and p38 mapk pathways”, AACR Annual Meeting, New Orleans, LA, 2016.
96. Kulkarni AA, Sabbisetti V, Sengupta S. “Supramolecular nanoparticles that target mapk pathway synergizes with immune checkpoint inhibitor in melanoma”, AACR Annual Meeting, Philadelphia, PA, 2015.
Kulkarni AA was awarded the AACR Scholar-in-Training award for this paper